Efficacy of pegylated recombinant human granulocyte colony-stimulating factor in preventing neutropenia induced by TPF chemotherapy in head and neck cancer
SONG Jiayu
GONG Xiuyun
JIN Feng
WU Weili
LI Yuanyuan
LONG Jinhua
LUO Xiuling
CHEN Xiaoxiao
WANG Limin
Abstract：Objective To investigate the clinical application value of long-acting pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)in the prevention of neutropenia following docetaxel,cisplatin,and fluorouracil(TPF)regimen chemotherapy in patients with head and neck cancer.Methods One hundred and six patients with locally advanced head and neck cancer,who were admitted to the Affiliated Cancer Hospital of Guizhou Medical University between June 2019 and June 2023,were included in this study.All patients received TPF regimen chemotherapy and underwent long-acting neutropenia prevention with PEG-rhG-CSF.After excluding 11 cases with incomplete data,a total of 95 cases were eventually included for analysis,consisting of the primary prevention(PP)group(n=47)and the secondary prevention(SP)group(n=48).The main observation indicators included the incidence of chemotherapy-induced neutropenia(CIN),febrile neutropenia(FN),antibiotic usage,the rate of chemotherapy dose reduction,and the incidence and duration of delays in the next chemotherapy cycle.Results Compared with the PP group,the SP group showed a significantly lower incidence of FN in the first cycle,with a reduction of 23.6％(P＜0.05).During the first cycle,the time to neutrophil nadir was significantly shorter in the SP group than in the PP group[(5.02±3.65)d vs.(6.32±3.42)d,P＜0.05],the time to neutrophil recovery was significantly earlier in the SP group[(5.38±3.94)d vs.(6.98±3.81)d,P＜0.01],and the duration of neutropenia was also shorter in the SP group[(0.35±0.60)d vs.(0.66±0.76)d,P＜0.05].In the second cycle,the duration of neutropenia was shorter in the PP group than in the SP group(P＜0.05).Conclusion Preventive leukocyte elevation therapy with PEG-rhG-CSF can effectively reduce the incidence and severity of CIN and FN in head and neck cancer patients undergoing TPF chemotherapy.
Keywords：head and neck tumorspegylated recombinant human granulocyte colony-stimulating factorlong-acting leukocyte elevation therapydocetaxelcisplatinand fluorouracil regimenneutropeniaprevention
Publication Date：2026-01-28
Online Publishing Date：2026-03-18(First online date of this platform, not the publication date of the document)
Pages：7( 79-85 )